Title
Phase II Dose Titration Study in Patients With Neuropathic Pain
A Phase II, Multicentre, Pilot, Randomised, Double Blind Placebo Controlled Dose Titration Study to Evaluate the Safety, Maximum Tolerated Dose and Preliminary Evidence of Efficacy of Orally Administered Ralfinamide at Four Doses (80, 160, 240 and 320 mg/Day) in Patients With Neuropathic Pain
Phase
Phase 2Lead Sponsor
Newron PharmaceuticalsStudy Type
InterventionalStatus
Completed No Results PostedIndication/Condition
Neuropathic PainIntervention/Treatment
ralfinamide ...Study Participants
272The purpose of this study is to examine the effects of various increasing doses of Ralfinamide in patients with neuropathic pain.
Oral tablets administered at rising doses of 80 - 320 mg/day
Inclusion Criteria: Male or female patients Females post-menopausal for at least 12 months, 24 months in India, Poland, and Austria Diagnosed by neurologist with current neuropathic pain Exclusion Criteria: See inclusion criteria